A Risk-Benefit Assessment of HIV Protease Inhibitors
- 1 January 1999
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 20 (4) , 299-321
- https://doi.org/10.2165/00002018-199920040-00002
Abstract
The use of triple therapy regimens, often called highly active antiretroviral therapy (HAART), generally involving 2 nucleoside analogues and an HIV protease inhibitor, have been endorsed as the...Keywords
This publication has 72 references indexed in Scilit:
- Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team.1998
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998
- A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitorsAIDS, 1998
- Antiretroviral Therapy for HIV InfectionDrugs, 1998
- Peripheral Neuropathy with Nucleoside AntiretroviralsDrug Safety, 1998
- Renal Dysfunction in a Human Immunodeficiency Virus–Infected Patient Who Was Treated with IndinavirClinical Infectious Diseases, 1997
- Clinical Efficacy of Monotherapy with Stavudine Compared with Zidovudine in HIV-Infected, Zidovudine-Experienced PatientsAnnals of Internal Medicine, 1997
- Improved compliance measures: Applications in an ambulatory hypertensive drug trialClinical Pharmacology & Therapeutics, 1990
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging.Journal of Clinical Investigation, 1989